CPC C07K 16/2863 (2013.01) [C07K 16/2878 (2013.01); A61K 39/39541 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01)] | 6 Claims |
1. An anti-4-1BB/anti-EGFR bispecific antibody comprising:
(a) a 4-1BB targeting moiety which is an anti-4-1BB scFv, and
(b) an EGFR targeting moiety which is a full-length form of an anti-EGFR antibody, and
wherein the anti-4-1BB scFv comprises:
(1) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
(2) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 8, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; or
(3) an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 9, an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, and
wherein the anti-EGFR antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO: 73, or 74; and
a light chain comprising the amino acid sequence of SEQ ID NO: 75.
|